Comparative Pharmacology
Head-to-head clinical analysis: PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE versus TARACTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE versus TARACTAN.
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE vs TARACTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Perphenazine is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with additional antagonism at serotonin 5-HT2, alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors. Amitriptyline is a tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake, also antagonizing histamine H1, alpha-1 adrenergic, and muscarinic M1 receptors.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Oral: Perphenazine 2-4 mg with amitriptyline 10-50 mg, administered 3-4 times daily. Maximum daily dose: perphenazine 24 mg, amitriptyline 150 mg.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
None Documented
None Documented
Perphenazine: ~9-12 hours (range 8-20 h). Amitriptyline: ~15-24 hours (range 10-50 h). Clinical context: Steady-state reached in 3-10 days; amitriptyline's active metabolite nortriptyline has T½ ~18-35 h.
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Perphenazine: renal (0.5-2% unchanged), hepatic metabolism and biliary/fecal elimination (major). Amitriptyline: renal (<5% unchanged, 30-50% as metabolites), biliary/fecal (significant). Combined: ~70-80% renal (metabolites), ~20-30% fecal.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic